Cargando…
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Autores principales: | Lee, Yun Bin, Lee, Jeong-Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628003/ https://www.ncbi.nlm.nih.gov/pubmed/28942622 http://dx.doi.org/10.3350/cmh.2017.0045 |
Ejemplares similares
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016) -
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017) -
A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B
por: Jindal, Ankur, et al.
Publicado: (2019) -
Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
por: Manik, Abul H, et al.
Publicado: (2021) -
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
por: Seo, Hee Yeon, et al.
Publicado: (2017)